- Home
- AARD vs FATE Comparison
AARD vs FATE Comparison
Compare AARD & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | FATE |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 125.6M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AARD | FATE |
|---|---|---|
| Price | $5.56 | $2.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $15.29 | $4.10 |
| AVG Volume (30 Days) | 125.5K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.35 | $0.95 |
| 52 Week High | $17.94 | $3.23 |
Technical Indicators
Market Signals| Indicator | AARD | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 51.80 |
| Support Level | $5.47 | $2.27 |
| Resistance Level | $6.01 | $2.55 |
| Average True Range (ATR) | 0.55 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 59.53 | 55.42 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.